Celldex Therapeutics Inc CLDX:NASDAQ

Last Price$34.20NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/18/22

Today's Change-2.53(6.89%)
Bid (Size)$19.68 (4)
Ask (Size)$38.40 (5)
Day Low / High$33.40 - 36.65
Volume699.3 K

View Medical Specialties IndustryPeer Comparison as of 08/18/2022


Celldex Therapeutics Inc ( NASDAQ )

Price: $34.20
Change: -2.53 (6.89%)
Volume: 699.3 K
4:00PM ET 8/18/2022

Nevro Corp ( NYSE )

Price: $50.78
Change: +0.13 (0.26%)
Volume: 297.0 K
7:00PM ET 8/18/2022

Silk Road Medical Inc ( NASDAQ )

Price: $44.83
Change: +0.54 (1.22%)
Volume: 300.2 K
4:00PM ET 8/18/2022

Transmedics Group Inc ( NASDAQ )

Price: $46.46
Change: +2.95 (6.78%)
Volume: 460.4 K
4:00PM ET 8/18/2022

Avanos Medical Inc ( NYSE )

Price: $27.13
Change: -0.33 (1.20%)
Volume: 175.3 K
7:00PM ET 8/18/2022

Read more news Recent News

Insider Sell: Celldex Therapeutics
4:23PM ET 8/17/2022 MT Newswires

Richard M. Wright, Senior Vice President and Chief Commercial Officer, on August 15, 2022, sold 15,328 shares in Celldex Therapeutics (CLDX) for $578,048....

Insider Sell: Celldex Therapeutics
4:15PM ET 8/17/2022 MT Newswires

Anthony S Marucci, Director, President and CEO, on August 15, 2022, sold 120,000 shares in Celldex Therapeutics (CLDX) for $4,519,572. Following the Form 4...

Insider Sell: Celldex Therapeutics
4:27PM ET 8/15/2022 MT Newswires

Samuel Bates Martin, Senior Vice President and Chief Financial Officer, on August 11, 2022, sold 20,000 shares in Celldex Therapeutics (CLDX) for $730,485....

--SVB Securities Adjusts Celldex Therapeutics' Price Target to $64 From $68, Keeps Outperform Rating
10:59AM ET 8/09/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionCelldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ. View company web site for more details
AddressPerryville III Building
Hampton, New Jersey 08827
Number of Employees137
Recent SEC Filing08/17/20224
President, Chief Executive Officer & DirectorAnthony S. Marucci
CFO, Secretary, Treasurer & Senior Vice PresidentSam Martin
Chief Scientific Officer & Executive VPTibor Keler
Chief Medical Officer & Senior Vice PresidentDiane C. Young

Company Highlights

Price Open$36.64
Previous Close$34.20
52 Week Range$19.85 - 57.20
Market Capitalization$1.6 B
Shares Outstanding46.8 M
SectorHealth Technology
IndustryMedical Specialties
Next Earnings Announcement11/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.00
Beta vs. S&P 500N/A
Revenue$9.5 M
Net Profit Margin-12,093.93%
Return on Equity-24.62%

Analyst Ratings as of 09/16/2021

Consensus RecommendationConsensus Icon
Powered by Factset